COMPANY
Acura Pharmaceuticals Inc.
Acura is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing the Company's proprietary LIMITX™, IMPEDE® and AVERSION® Technology platforms. From company website Source · Oct 12, 2026
Timeline
- Trial start Phase 2: Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users source ↗
- Trial start Phase 2: Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users source ↗
- Trial start Phase 2: Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse source ↗
- Trial start Phase 3: Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy source ↗
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT01030406 | Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users | Phase 2 | Completed | 2010-01 | 2010-02 (actual) |
| NCT01759446 | Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users | Phase 2 | Completed | 2013-02 | 2013-04 (actual) |
| NCT00699010 | Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse | Phase 2 | Completed | 2008-03 | 2008-08 (actual) |
| NCT00654069 | Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy | Phase 3 | Completed | 2007-09 | 2008-02 (actual) |
NIH awards 1
- NIH award 1R44DA037921-01 FY2014: $299,694 awarded for that fiscal year; activity R44 (SBIR); PI BRZECZKO, ALBERT W; recipient as written: ACURA PHARMACEUTICALS, INC., PALATINE, IL. A proposal to develop a self-regul source ↗